Navigating CIDP Guidelines, Misdiagnosis, and Disease Variants

In this episode, "Navigating CIDP Guidelines, Misdiagnosis, and Disease Variants," the panelists in neurology and neuromuscular medicine explore the practical utility of the 2021 EAN/PNS CIDP guidelines and the considerable complexity introduced by disease variants. The discussion opens with a question about monophasic CIDP, with one expert noting that 20–30% of patients can achieve drug-free remission after initial treatment, suggesting a subset of patients experience a self-limiting course that nonetheless meets the diagnostic threshold of progression or relapse beyond two months.

Regarding the 2021 EAN/PNS guidelines, panelists acknowledge that while academic neuromuscular centers tend to follow them more closely, adoption among general neurologists remains inconsistent. The guidelines are characterized as a valuable blueprint for integrating clinical features, electrodiagnostic findings, and the exclusion of CIDP mimics, though their complexity is cited as a barrier to routine use. Emerging app-based and web-based tools are briefly noted as practical resources for distilling guideline recommendations into more accessible formats.

The panel then examines CIDP variants, which collectively represent a significant driver of both overdiagnosis and underdiagnosis. Distal CIDP is identified as particularly challenging, as its presentation closely resembles common neuropathies, making electrodiagnostic findings and treatment response critical for confirmation. Sensory CIDP presents its own difficulties, as the absence of weakness complicates response assessment. Motor CIDP can mimic myopathy or even ALS, underscoring the importance of nerve conduction studies. Focal and multifocal CIDP round out the discussion, with experts noting that conduction slowing at entrapment sites can obscure the multifocal picture. Panelists note that typical CIDP accounts for roughly 50–60% of cases, while variants each represent approximately 5–10%, and that about half of variant cases may evolve into a typical phenotype over time.

The next episode in this series, "CIDP Quality of Life Impact and Unmet Needs," features the panelists discussing the broad impact of CIDP on quality of life and the importance of multidisciplinary management beyond immunotherapy, before turning to an open discussion on the field's greatest unmet needs, including earlier diagnosis, more effective therapies, and the development of diagnostic and disease activity biomarkers.